Table 3.
Immune Checkpoint blockade + anti-angiogenic agents | |||
---|---|---|---|
Clinical trial | Condition | Phase | Intervention |
NCT02348008 | CCmRC | Phase I/II | Pembrolizumab+Bevacizumab |
NCT02014636 | CCmRC | Phase I | Pazopanib Pembrolizumab Pembrolizumab+Pazopanib |
NCT01472081 | CCmRC | Phase I | Nivolumab+Ipilimumab Nivolumab+Pazopanib Nivolumab+ Sunitinib |
NCT02337491 | Glioblastoma | Phase II | Pembrolizumab Pembrolizumab+Bevecizumab |
NCT02501096 | Solid tumors | Phase I/II | Pembrolizumab+Lenvatinib |
CCmRC = clear cell metastatic renal cancer;